ESMO 2024丨Dr. Junyuan Qi: Cutting Through the Fog, Promising Phase I Results for the New BCL-2 Inhibitor in R/R NHL and AML

ESMO 2024丨Dr. Junyuan Qi: Cutting Through the Fog, Promising Phase I Results for the New BCL-2 Inhibitor in R/R NHL and AML

2024.10.12
From September 13th to 17th, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the world's top oncology conferences, it brought together experts and scholars from across the globe to share cutting-edge research findings and discuss future directions. At the session dedicated to hematologic malignancies, Dr. Junyuan Qi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented the first-in-human study of the BCL-2 inhibitor TQB3909 in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML), showing promising results. Hematology Frontier invited Professor Qi to provide an in-depth analysis of the study and discuss the future clinical applications and research directions for this novel BCL-2 inhibitor.
Dr. Yao Zhu: Tailoring Prostate Cancer Treatment in China, Fudan University Shanghai Cancer Center’s Team Explores Strategies to Benefit More Patients

Dr. Yao Zhu: Tailoring Prostate Cancer Treatment in China, Fudan University Shanghai Cancer Center’s Team Explores Strategies to Benefit More Patients

2024.10.12
Due to factors such as early screening, drug accessibility, and genetic differences, prostate cancer characteristics in China differ from those in Western countries. In recent years, with China's aging population, the incidence and mortality of prostate cancer have risen significantly, increasing the disease burden. At the recent CSCO Annual Meeting, Urology Frontier invited Dr. Yao Zhu from Fudan University Shanghai Cancer Center to share insights on the characteristics of prostate cancer in China, the latest research progress at Fudan, and the value of clinical research by physicians.
CUA 2024丨Dr. Jian Huang Shares Key Areas of Focus at the CUA Annual Meeting and Sun Yat-sen Memorial Hospital ’s Bladder Cancer Research

CUA 2024丨Dr. Jian Huang Shares Key Areas of Focus at the CUA Annual Meeting and Sun Yat-sen Memorial Hospital ’s Bladder Cancer Research

2024.10.12
The 31st Urology Academic Conference, organized by the Chinese Medical Association and the Chinese Urological Association (CUA), was held from September 19 to 22, 2024, at the National Convention Center in Tianjin. This event brought together leading urology experts from China and abroad to discuss the latest advances in clinical research and surgical treatment. After the conference, Urology Frontier invited Dr. Jian Huang, Chair of the CUA and Director of Urology at Sun Yat-sen Memorial Hospital, Sun Yat-sen University, to share insights on the meeting's focus areas, the application of artificial intelligence (AI) in bladder cancer, and the research directions of his team.
Dr. Qiang Wei: Precision Endocrine Therapy for Prostate Cancer Enters a New Era as the West China Hospital Continues to Pioneer Diagnostic

Dr. Qiang Wei: Precision Endocrine Therapy for Prostate Cancer Enters a New Era as the West China Hospital Continues to Pioneer Diagnostic

2024.10.12
Prostate cancer is one of the most common malignancies in men, with endocrine therapy being a standard treatment approach. However, it often comes with some side effects. Recently, the 31st Annual Urology Conference, hosted by the Chinese Medical Association and the Chinese Urological Association (CUA), was held from September 19-22, 2024, at the Tianjin National Convention Center. Following the event, Urology Frontier invited Dr. Qiang Wei from West China Hospital, Sichuan University to share insights on the latest advancements in endocrine therapy for prostate cancer, side effect management, and the future research directions of his team.
CSCO 2024丨Dr. Ou Bai: The Development and Growth of the Lymphoma Specialty at The First Bethune Hospital of Jilin University

CSCO 2024丨Dr. Ou Bai: The Development and Growth of the Lymphoma Specialty at The First Bethune Hospital of Jilin University

2024.10.12
From September 25-29, 2024, the "27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting," hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, will be held in Xiamen. The conference, themed "Patient-Centered, Sharing the Future," brings together the latest research advancements and developments in the field, both domestically and internationally. For more than 20 years, CSCO has been at the forefront of clinical oncology in China, with experts deeply involved in its growth, advancing their careers through this platform. Hematology Frontier has launched a special "Growing with CSCO" series, inviting Chinese scholars to revisit past stories. In this issue, we invited Dr. Ou Bai, a member of the CSCO United Committee for Lymphoma Intervention (UCLI) and a key figure in the development of the lymphoma specialty at The First Bethune Hospital of Jilin University, to share the story of growing together with CSCO.
CSCO 2024丨Dr. Sanjun Cai: Perioperative “Three-Pronged Strategy” Brings More Options for Colorectal Cancer Treatment

CSCO 2024丨Dr. Sanjun Cai: Perioperative “Three-Pronged Strategy” Brings More Options for Colorectal Cancer Treatment

2024.10.11
From September 25 to 29, 2024, the 27th Annual National Clinical Oncology Conference and CSCO Academic Annual Meeting was successfully held in Xiamen. With the theme "Patient-Centered, Sharing the Future," the conference gathered significant research progress and developments from both domestic and international fields. Dr. Sanjun Cai from Fudan University Shanghai Cancer Center chaired the special session on perioperative treatment for colorectal cancer at this year’s conference. During the event, Oncology Frontier conducted an interview with Professor Cai to discuss recent advances and challenges in perioperative colorectal cancer treatment. Below is a summary of the interview to provide insight for the readers.
CSCO 2024 | Dr. Gong Chen Provides an In-Depth Analysis of the Changing Treatment Paradigm for Locally Advanced Colorectal Cancer

CSCO 2024 | Dr. Gong Chen Provides an In-Depth Analysis of the Changing Treatment Paradigm for Locally Advanced Colorectal Cancer

2024.10.11
From September 25 to 29, 2024, the much-anticipated 27th Annual Chinese Society of Clinical Oncology (CSCO) conference was held successfully in Xiamen. This prominent event gathered top experts from China's oncology community, focusing on standardized pathways and cutting-edge advancements in the diagnosis and treatment of malignant tumors.During the conference, Dr. Gong Chen from the Sun Yat-sen University Cancer Center delivered a well-received presentation titled "The Evolving Treatment Paradigm for Locally Advanced Colorectal Cancer." In this golden moment of academic exchange, Oncology Frontier conducted a deep interview with Professor Chen. The discussion centered around the latest advancements in the treatment of locally advanced colorectal cancer and his long-standing academic connection with CSCO, offering an insightful blend of professional wisdom and personal emotion.